Kuldeep Singh Sachdeva

Kuldeep Singh Sachdeva

Auto-generated profile, based on publicly available information

Kuldeep Singh Sachdeva

Central TB Division, Ministry of Health & Family Welfare, New Delhi, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NANimalan Arinaminpathy
Nimalan Arinaminpathy
DBDeepak Batra
Deepak Batra
NMNilesh Maheshwari
Nilesh Maheshwari
KSKishan Swaroop
Kishan Swaroop
LSLokesh Sharma
Lokesh Sharma
PDPuneet Dewan
Puneet Dewan
There is a pressing need for systematic approaches for monitoring how much TB treatment is ongoing in the private sector in India: both to cast light on the true scale of the problem, and to help monitor the progress of interventions currently being planned to address this problem. We used commercially available data on the sales of rifampicin-containing drugs in the private sector, adjusted for data coverage and indication of use. We examined temporal, statewise trends in volumes (patient-months) of TB treatment from 2013 to 2016. We additionally analysed the proportion of drugs that were sold in combination packaging (designed to simplify TB treatment), or as loose pills. Drug sales suggest a steady trend of TB treatment dispensed by the private sector, from 18.4 million patient-months (95% CI 17.3–20.5) in 2013 to 16.8 patient-months (95% CI 15.5–19.0) in 2016. Overall, seven of 29 states in India accounted for more than 70% of national-level TB treatment volumes, including Uttar Pradesh, Maharashtra and Bihar. The overwhelming majority of TB treatment was dispensed not as loose pills, but in combination packaging with other TB drugs, accounting for over 96% of private sector TB treatment in 2017. Our findings suggest consistent levels of TB treatment in the private sector over the past 4 years, while highlighting specific states that should be prioritized for intervention. Drug sales data can be helpful for monitoring a system as large, disorganised and opaque as India’s private sector.

19 March 2025 in IJID Regions
Verified
Journal Article
Open access
AZAlimuddin Zumla
Alimuddin Zumla
SSSuvanand Sahu
Suvanand Sahu
LDLucica Ditiu
Lucica Ditiu
USUrvasha Singh
Urvasha Singh
YPYoung-Joon Park
Young-Joon Park
EPEskild Petersen
Eskild Petersen
• The WHO End TB strategy is stalling as shown in the Global Tuberculosis Report 2023. • The main reason is unequal access to tuberculosis diagnosis and treatment. • Tuberculosis diagnosis and treatment must be expanded outside urban centers down to the smallest and most remote unit. • Screening risk populations for latent tuberculosis will help identify infected persons before they develop active tuberculosis.

31 August 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
RRRajesh Raju
Rajesh Raju
BPBanuru Prasad
Banuru Prasad
UAUmesh Alavadi
Umesh Alavadi
Sanjeev SainiSanjeev Saini
Sanjeev Saini
MSMukesh Sabharwal
Mukesh Sabharwal
RJRajendra P. Joshi
Rajendra P. Joshi
The complete diagnostic evaluation of tuberculosis based on its drug-resistance profile is critical for appropriate treatment decisions. The TB diagnostic landscape in India has been transformed with the scaling-up of WHO-recommended diagnostics, but challenges remain with specimen transportation, completing diagnostic assessment, turnaround time (TAT), and maintaining laboratories. Private laboratories have demonstrated efficiencies for specimen collection, transportation, and the timely testing and issue of results. A one-stop TB diagnostic model was designed to assess the feasibility of providing end-to-end diagnostic services in the Hisar district of Haryana state, India. A NTEP-certified private laboratory was engaged to provide the services, complementing the existing public sector diagnostic services. A total of 10,164 specimens were collected between May 2022 and January 2023 and these were followed for the complete diagnostic assessment of Drug-Susceptible TB (DS-TB) and Drug-Resistant TB (DR-TB) and the time taken for issuing results. A total of 2152 (21%) patients were detected with TB, 1996 (93%) Rifampicin-Sensitive and 134 (6%) with Rifampicin-Resistant TB. Nearly 99% of the patients completed the evaluation of DS-TB and DR-TB within the recommended TAT. The One-Stop TB/DR-TB Diagnostic Solution model has demonstrated that diagnostic efficiencies could be enhanced through the strategic purchase of private laboratory services.